Literature DB >> 15289737

Nonocular second primary tumors after retinoblastoma: retrospective study of 111 patients treated by electron beam radiotherapy with or without TEM.

Pierre Schlienger1, François Campana, Jacques Robert Vilcoq, Bernard Asselain, Rémi Dendale, Laurence Desjardins, Thierry Dorval, Erica Quintana, José Rodriguez.   

Abstract

The objective of this study was to assess the role of various clinical and treatment factors involved in the long-term incidence of nonocular second primary tumors following retinoblastoma. The study was based on 111 patients treated between 1963 and 1977 according to the same radiotherapy protocol (electron beam radiotherapy) alone or in combination with triethylene melamine (TEM). Various statistical methods were used to obtain the actuarial survival curve, the cumulative incidence of second primary tumors, and comparisons of patient groups and subgroups. The 5-, 10-, 20-, and 30-year survival rates were 75%, 70%, 63%, and 55% with a follow-up of 23 to 35 years. The study reports the various parameters concerning 111 children and 17 second primary tumors: sex, age at treatment, histology of the retinoblastoma and second primary tumors, site of second tumors (anatomic and compared with irradiation field), radiation dose, time to onset, and chemotherapy with or without TEM. The results are discussed and compared with the data reported in the literature. Electron beam radiotherapy at a dose of 45 Gy does not eliminate the risk of nonocular second primary tumors. TEM also does not modify survival or the overall incidence of second primary tumors, but significantly increases the risk of second primary tumors outside the irradiation field.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15289737     DOI: 10.1097/01.coc.0000128861.46357.ee

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  4 in total

Review 1.  Recommendations for Long-Term Follow-up of Adults with Heritable Retinoblastoma.

Authors:  Emily S Tonorezos; Danielle Novetsky Friedman; Dana Barnea; Machteld I Bosscha; Guillermo Chantada; Charlotte J Dommering; Pim de Graaf; Ira J Dunkel; Armida W M Fabius; Jasmine H Francis; Mary-Louise C Greer; Ruth A Kleinerman; Wijnanda A Kors; Suzanne Laughlin; Annette C Moll; Lindsay M Morton; Petra Temming; Margaret A Tucker; Flora E van Leeuwen; Michael F Walsh; Kevin C Oeffinger; David H Abramson
Journal:  Ophthalmology       Date:  2020-05-15       Impact factor: 12.079

2.  Risk of subsequent malignant neoplasms in long-term hereditary retinoblastoma survivors after chemotherapy and radiotherapy.

Authors:  Jeannette R Wong; Lindsay M Morton; Margaret A Tucker; David H Abramson; Johanna M Seddon; Joshua N Sampson; Ruth A Kleinerman
Journal:  J Clin Oncol       Date:  2014-09-02       Impact factor: 44.544

Review 3.  Familial and genetic risk of transitional cell carcinoma of the urinary tract.

Authors:  Christine M Mueller; Neil Caporaso; Mark H Greene
Journal:  Urol Oncol       Date:  2008-06-18       Impact factor: 3.498

4.  Use of combination therapy with cisplatin and calcitriol in the treatment of Y-79 human retinoblastoma xenograft model.

Authors:  A D Kulkarni; P R van Ginkel; S R Darjatmoko; M J Lindstrom; D M Albert
Journal:  Br J Ophthalmol       Date:  2009-03-30       Impact factor: 4.638

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.